“Ozempic and sleep apnea” is a common search, but the strongest, FDA-approved evidence here actually belongs to a different, related drug. Tirzepatide (sold as Zepbound for weight management and Mounjaro for diabetes) became the first and only FDA-approved medication specifically for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, based on results from the SURMOUNT-OSA trial published in the New England Journal of Medicine. Participants saw their apnea-hypopnea index (a measure of breathing interruptions during sleep) drop by roughly 55 percent, compared to about 5 percent with placebo, alongside close to 20 percent body weight loss, with nearly half of participants experiencing full resolution of their OSA. Semaglutide (Ozempic, Wegovy) has shown substantial weight loss in its own trials and weight loss is well-established to improve OSA, but it doesn’t have the same dedicated, large-scale OSA outcome trial that tirzepatide does. This is educational information, not medical advice.
From the Practice
[RILEY: add a real observation here, for example how often clients ask about GLP-1 medications specifically for sleep apnea, or how you help someone think through this alongside CPAP use.]
What Did the SURMOUNT-OSA Trial Actually Find?
The SURMOUNT-OSA program consisted of two separate 52-week, phase 3, randomized, placebo-controlled trials, both in adults with moderate-to-severe OSA and obesity. One trial (Study 1) included people not currently using positive airway pressure (PAP) therapy; the other (Study 2) included people who were already using PAP and planned to continue.
The results, published in the New England Journal of Medicine, were substantial. In Study 1, tirzepatide produced a mean reduction in apnea-hypopnea index (AHI) of about 55 percent from baseline, compared to roughly 5 percent with placebo. In Study 2 (the PAP-using group), tirzepatide reduced AHI by a mean of 30.4 events per hour, compared to 6.0 events per hour with placebo. Body weight dropped by an average of about 18 to 20 percent with tirzepatide, compared to roughly 1 to 2 percent with placebo. Notably, nearly half of trial participants experienced full resolution of their OSA. Beyond AHI and weight, tirzepatide also reduced hypoxic burden (a measure of how much and how often oxygen levels drop during sleep), reduced a key inflammation marker (hsCRP), lowered systolic blood pressure, and improved patient-reported sleep disturbance and quality of life measures.
At a Glance: SURMOUNT-OSA Trial Results
| Measure | Tirzepatide | Placebo |
|---|---|---|
| AHI reduction, Study 1 (no PAP) | ~55% from baseline | ~5% from baseline |
| AHI reduction, Study 2 (on PAP) | 30.4 events/hour | 6.0 events/hour |
| Body weight change | ~18-20% loss | ~1-2% loss |
| Participants with full OSA resolution | Nearly half | Substantially lower |
| Most common side effects | Mild-to-moderate GI symptoms | — |
Why Would a Weight-Management Drug Improve Sleep Apnea?
The mechanism here is straightforward and fits squarely into a root-cause framework: obesity is one of the most significant, well-established risk factors for obstructive sleep apnea, since excess fat around the neck and upper airway increases the likelihood of airway collapse during sleep. Tirzepatide isn’t acting on the airway directly, it’s producing substantial weight loss, which in turn reduces the anatomical driver of airway obstruction. This is meaningfully different from most OSA treatments, which manage the mechanical symptom (like PAP therapy, which keeps the airway open with pressurized air) rather than addressing the underlying weight-related cause.
Is This the Same Thing as “Ozempic” for Sleep Apnea?
Not exactly, and this distinction is worth understanding clearly. Semaglutide (the active ingredient in Ozempic and Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Zepbound, Mounjaro) is a dual GIP and GLP-1 receptor co-agonist, a related but distinct medication that activates two different hormone pathways instead of one. Semaglutide has demonstrated substantial weight loss in its own large trials, in one 104-week trial, semaglutide produced a mean body weight change of about 15.2 percent compared to 2.6 percent with placebo, and weight loss of this scale would be expected to meaningfully improve OSA given the well-established link between the two.
However, tirzepatide is the medication with the dedicated, large-scale, FDA-approved trial specifically measuring OSA outcomes (SURMOUNT-OSA), making it the drug with direct, rigorous evidence in this specific area. When people search “Ozempic and sleep apnea,” they’re often really asking about this broader drug class and its weight-loss-driven effect on OSA, but the strongest, most specific evidence currently sits with tirzepatide, not semaglutide itself.
Does This Mean You Can Stop Using CPAP?
Not necessarily, and this isn’t a decision to make without medical guidance. The SURMOUNT-OSA trial specifically studied tirzepatide both in people not using PAP and in people continuing PAP therapy, finding meaningful benefit in both groups, suggesting it may work well as a complement to, not necessarily a replacement for, existing OSA treatment. Even with a 55 percent average AHI reduction, “nearly half” achieving full resolution means a substantial portion of participants still had residual OSA requiring ongoing management. Whether and how to adjust PAP use alongside a GLP-1 medication is a decision to make with a sleep medicine provider, based on your individual severity and response, not something to determine on your own.
If weight and sleep apnea are both part of your picture, book a consultation with The Sleep Consultant so we can help you think through the full range of options available to you.
What the Research Shows
Tirzepatide is the first FDA-approved medication specifically for obesity-related obstructive sleep apnea. Based on the SURMOUNT-OSA trials published in the New England Journal of Medicine, this approval reflects substantial reductions in breathing disruptions during sleep, not just general weight loss claims.
The trial results were large by clinical standards. Participants saw AHI reductions of roughly 55 percent in one trial arm, alongside 18-20 percent body weight loss, with nearly half of participants achieving full resolution of their OSA, a considerably larger effect than most non-surgical OSA interventions.
The mechanism runs through weight loss, addressing a root cause of OSA, not a direct airway effect. Since obesity is a well-established driver of airway collapse during sleep, tirzepatide’s substantial weight-loss effect is understood to be the primary pathway behind its OSA benefit, rather than an independent respiratory mechanism.
Tirzepatide and semaglutide are related but distinct drugs, and the dedicated OSA evidence belongs specifically to tirzepatide. While semaglutide (Ozempic, Wegovy) has shown substantial weight loss in its own right, which would be expected to benefit OSA, it doesn’t have the same large-scale, FDA-approved, OSA-specific outcome trial that tirzepatide has completed.
This article is for educational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment.
Want to Address Sleep Apnea and Weight Together?
Join the free Sleep Nirvana Club course and community for practical, root-cause-first guidance: Join here
When to Seek Professional Help
- You have obesity and diagnosed or suspected obstructive sleep apnea and want to understand your full range of treatment options
- You’re currently on PAP therapy and considering whether a GLP-1 medication might change your treatment plan; this should be a joint decision with your sleep medicine provider
- You’re considering a GLP-1 medication and want to understand the realistic range of outcomes, including the possibility of residual OSA even with significant improvement
- You experience gastrointestinal side effects from a GLP-1 medication that are difficult to manage
- You haven’t been formally diagnosed with OSA but suspect it, given symptoms like loud snoring, witnessed breathing pauses, or excessive daytime sleepiness
Frequently Asked Questions
Does Ozempic actually help with sleep apnea?
Semaglutide, the active ingredient in Ozempic, has produced substantial weight loss in its own trials, and weight loss is well-established to improve OSA. However, the specific, FDA-approved, large-scale trial demonstrating direct OSA improvement was conducted with tirzepatide (Zepbound, Mounjaro), a related but different medication, not semaglutide itself.
What did the SURMOUNT-OSA trial actually find?
It found that tirzepatide produced a mean AHI (apnea-hypopnea index) reduction of about 55 percent from baseline in one trial arm, alongside roughly 18-20 percent body weight loss, with nearly half of participants achieving full resolution of their obstructive sleep apnea.
How does a weight-loss drug improve sleep apnea?
Obesity is one of the most significant risk factors for obstructive sleep apnea, since excess fat around the neck and airway increases the likelihood of airway collapse during sleep. Tirzepatide’s substantial weight-loss effect addresses this underlying anatomical driver, rather than acting directly on the airway itself.
Can I stop using my CPAP machine if I start a GLP-1 medication?
Not automatically. The SURMOUNT-OSA trial found benefit in both people using and not using PAP therapy, but a substantial portion of participants still had some residual OSA even after significant improvement. This is a decision to make with a sleep medicine provider based on your individual case, not something to decide independently.
Is tirzepatide the same as Ozempic?
No. Ozempic’s active ingredient is semaglutide, a GLP-1 receptor agonist. Tirzepatide (Zepbound, Mounjaro) is a dual GIP and GLP-1 receptor co-agonist, a related but distinct medication, and it’s the one with the dedicated, FDA-approved trial specifically for obstructive sleep apnea.
When to Work With a Sleep Consultant
GLP-1 medications represent a genuinely significant, evidence-backed development for weight-related sleep apnea, but the details matter, which drug, what the trial actually measured, and how it fits alongside existing treatment. If weight and sleep apnea are both part of your picture, it’s worth understanding your full range of options.
